North America Checkpoint Inhibitors Market

North America Checkpoint Inhibitors Market Size (2024 to 2032)

The North America Checkpoint Inhibitors Market was valued at USD 3.83 billion in 2023. The North America Checkpoint Inhibitors Market is expected to have a 27.80 % CAGR from 2024 to 2032 and be worth USD 34.83 billion by 2032 from USD 4.89 billion in 2024.

The proliferation of cancer is a growth factor in the checkpoint Inhibitors market in North America. The rise in the prevalence of cancer across the region and the increase in awareness about checkpoint Inhibitors are projected to fuel the market during the forecast period.

However, technological advancements in the healthcare sector, such as screening procedures for cancer and government initiatives to alleviate cancer, are likely to augment the market growth. In addition, increasing healthcare expenditure and implementation of research and development activities by the major companies in the region are providing lucrative growth opportunities for the market players. Furthermore, an increase in investment and funding by the government and non-government organizations enables the entry of new market entrants, which most likely expand the regional market growth. 

Over the years, the major companies in the checkpoint inhibitor market in the region have formed partnerships or collaborations to develop advanced technologies such as bifunctional fusion protein or Y-trap. Bifunctional fusion protein or Y-trap is a therapy that was developed. But, unfortunately, most patients with cancer do not respond to immune checkpoint inhibitors. In the year 2018, researchers created the bifunctional fusion protein or Y-trap to improve the efficacy of immunotherapies. This medication is made by fusing a receptor for TGF-beta, a protein that targets checkpoint proteins including PD-L1 and CTLA-4. As a result, the y-trap targets both a checkpoint inhibitor and TGF-beta, providing a more effective approach to prevent immune suppression while also destroying the c-Reactive protein. 

However, the high cost associated with research activities is projected to restrain the market growth. Also, the lack of awareness and proper publicity for using these inhibitors in some areas restricts the North American checkpoint Inhibitors Market growth. 

This research report on the North America Checkpoint Inhibitors Market has been segmented and sub-segmented into the following categories.

North America Checkpoint Inhibitors Market - By Drug

• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4
• Chimeric Antigen Receptor T-cell
• Others

North America Checkpoint Inhibitors Market - By Application

• Lung cancer
• Renal cancer
• Blood cancer
• Bladder Cancer
• Hodgkin lymphoma
• Melanoma
• Others

North America Checkpoint Inhibitors Market - By Country

• The United States
• Canada
• Rest of North America

Geographically, the North American market is forecasted to dominate the global checkpoint inhibitors market over the forecast period. The growing population is the factor leading to an increase in hospitals and diagnostic centers in North America. Also, the increasing number of cancer incidences and rising government initiatives to improve awareness about diagnosis and treatment boost market growth. Over the forecast period, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications. In addition, several companies and academic institutions focus on novel treatment approaches, thus contributing to the immune checkpoint inhibitors market in North America.

The United States and Canada are the two most significant market growth contributors in the region, expanding the North American Checkpoint Inhibitors Market.

Over the forecast period, the United States dominated the market and is most likely to continue its growth during the forecast period. Advanced healthcare infrastructure, favorable reimbursement policies, and technological advancements are majorly propelling the market growth. According to the American Cancer Society, 1.7 million new cancer cases and 0.6 million cancer deaths occurred in the United States in 2019. Lung, prostate, bowel, and female breast cancer are the four most prevalent malignancies globally, accounting for 43 percent of all new cancer cases. Checkpoint inhibitors that target the checkpoints are effective cancer treatments. As a result, the increase in cancer incidence rates in North America is expected to drive demand for checkpoint inhibitors.

KEY MARKET PLAYERS

A few of the key market participants operating in the North America Checkpoint Inhibitors Market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.